The Effect of Rosuvastatin on Adenosine Metabolism

Adenosine Metabolism Clinical Trial

Official title:

Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00554138
• Other study ID #: Rosudip01
• Status: Completed
• Phase: N/A
• First received: November 5, 2007
• Last updated: September 22, 2008
• Start date: November 2007
• Est. completion date: April 2008

Study information

• Verified date: September 2008
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: April 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• age 18 - 50 years

• Signed informed consent

Exclusion Criteria:

• hypertension

• hypercholesterolemia

• diabetes Mellitus

• alanine aminotransferase > 90 U/L

• creatinine Kinase > 440 U/L

• cardiovascular disease

• GFR < 80 ml/min

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Adenosine Metabolism

Intervention

Drug:
• placebo
1 dd for 7-10 days
• rosuvastatin
1 dd 20 mg for 7-10 days

Locations

Country	Name	City	State
Netherlands	Radboud University Nijmegen Medical Centre	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	forearm vasodilatory response to dipyridamole		7 days
Secondary	lipid profile		7-10 days